Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil

PSYCHIATRY RESEARCH

卷:302

Article

Kelly, Deanna L.¹  Claxton, Amy²  Bidollari, Ilda²  Du, Yangchun² 

[1] Univ Maryland, Maryland Psychiat Res Ctr, Sch Med, 55 Wade Ave, Baltimore, MD 21228 USA

[2] Alkermes Inc, Waltham, MA USA

关键词: Antipsychotic agents;    Dopamine D2 receptor antagonists;    Hyperprolactinemia;    Sexual dysfunction physiological;    Drug switching;    Drug side effects;   

DOI  :  10.1016/j.psychres.2021.114030

来源: Elsevier

【 摘 要 】

One strategy to address hyperprolactinemia and associated sexual side effects in patients receiving antipsychotics is switching to an antipsychotic not associated with prolactin elevation (eg, aripiprazole). This post hoc analysis assessed prolactin concentrations and sexual side effects in an open-label prospective study of switching long-acting injectable antipsychotics from paliperidone palmitate (PP) to aripiprazole lauroxil (AL). Serum prolac-tin was measured throughout the study. Patient-reported sexual and endocrine side effects were assessed on the UKU Side Effect Rating Scale sexual function subscale and analyzed in study completers. Prior to starting AL treatment (screening), 49/50 (98%) patients had prolactin concentrations above the upper limit of normal (ULN; >13.13 ng/mL [males]; >26.72 ng/mL [females]). Six months after beginning AL treatment, prolactin levels were above ULN in 2/32 (6.3%) patients. Among 32 study completers, 81.3% reported sexual dysfunction in >= 1 domain at screening versus 56.3% at 6 months after starting AL treatment. Diminished sexual desire was the most common patient-reported sexual complaint at screening (46.9%); at 6 months, it was reported by 18.8%. In this post hoc analysis, the high levels of prolactin observed at screening decreased during AL treatment, and modest improvements in sexual side effects were evident in patients with schizophrenia.

【 授权许可】

Free